Clancy Paul J 4

What Happened
Paul J. Clancy, a director of Sionna Therapeutics, was granted a derivative equity award on June 17, 2026 for 17,340 shares. The Form 4 reports the transaction as an award (code A) with an acquisition price of $0.00 (total reported value $0.00). The instrument is identified as a derivative (an option) with vesting conditions described in the filing footnote.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-18 (timely filing).
• Transaction type: Award of a derivative security (transaction code A).
• Shares/options granted: 17,340; reported acquisition price: $0.00; total reported value: $0.00.
• Vesting: Footnote F1 — the option vests in full on the earlier of June 17, 2027 or the date of the next annual meeting, subject to the reporting person’s continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of sale or exercise in this filing — this is a grant, not a market purchase or disposition.

Context
This is a compensation-related grant to a board member that will vest in the future if the director remains in service. It is not an open-market buy or sale and does not represent an immediate cash transaction or exercise; such awards are common for director compensation and should be interpreted as a grant rather than a direct signal to buy or sell shares.